

13-valent Pneumococcal Conjugate Vaccine for Children 6 through 18 years old

Nancy M. Bennett, MD, MS
Pneumococcal Vaccines Work Group Chair
Advisory Committee on Immunization Practices
February 20, 2013

Pneumococcal Vaccines Work Group

ACIP members

Nancy Bennett (Chair)
Wendy Keitel
Jeffrey Duchin
Lorry Rubin

Ex Officio members

Mark Grabowsky
Kristin Nichol
Lucia Lee

Liaison Representatives

Rick Zimmerman
William Schaffner
Caroline Quach
Mary Glode
Jane Zucker
Lisa Jackson
Monica Farley
Kathy Neuzil
Julie Morita
Anthony Brenneman
Sandra Fryhofer

CDC

Tamara Pilishvili
Cynthia Whitney
Matt Moore
Tom Hennessy
Gina Mootrey
Ray Strikas
Jorge Arana
Maria Cano
Erin Kennedy
Carolyn Bridges

Pneumococcal Vaccines Work Group: Terms of Reference

- Review data on immunogenicity, efficacy, and cost-effectiveness of pneumococcal conjugate vaccines
- Determine whether data available to date on PCV13 immunogenicity, effectiveness, and efficacy are sufficient to determine value of immunizing with PCV13
- Develop a revised statement on pneumococcal immunization as necessary

Summary of Feb and Jun 2012 ACIP: PCV13 for Adults

- Reviewed and presented to ACIP evidence for PCV13 use among adults ≥ 50 years
- Deferred recommendation until more data available
 - Efficacy against pneumonia (CAPITA trial, results possibly in late 2013)
 - Indirect (herd) effects of PCV13 use in children
- ACIP voted to recommend PCV13 for adults 19 years or older with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants (Category A, evidence type 3)

13-valent Pneumococcal Conjugate Vaccine (PCV13) for Children 6 through 17 years old

- On January 25, 2013, the FDA approved Prevnar 13 for use in individuals 6 years through 17 years of age
- Children 5-9 years old: non-inferiority of the post-PCV13 IgG GMCs compared to the post-toddler IgG GMCs.
- Children 10-17 years old: non-inferiority of the OPA GMTs compared to children 5-9 years old.
- In this age group, PCV13 is indicated for the prevention of invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F

Pneumococcal Vaccines Work Group

Today's Presentations

1) Impact of PCV13 use in children	Dr. Matthew Moore (CDC/NCIRD)
2) PCV13 for children 6 through 18 years old with immunocompromising conditions: review of data and GRADE	Ms. Tamara Pilishvili (CDC/NCIRD)
3) Recommendations for PCV13 use among immunocompromised children 6 through 18 years old: Vote	Ms. Tamara Pilishvili (CDC/NCIRD)

Objective of today's session

- ❑ The WG will propose to change the current permissive (i.e. GRADE category B) recommendation for PCV13-naïve high-risk children 6 through 18 years old to a routine recommendation (GRADE category A)
- ❑ The evidence and rationale for this policy change will be presented
- ❑ We ask the ACIP to review the presented evidence and consider a vote on the proposed recommendation